Genome & Company (KOSDAQ:314130)
2,670.00
+65.00 (2.50%)
At close: Aug 4, 2025, 3:30 PM KST
HashiCorp Revenue
Genome & Company had revenue of 6.35B KRW in the quarter ending March 31, 2025, with 49.11% growth. This brings the company's revenue in the last twelve months to 29.84B, up 86.35% year-over-year. In the year 2024, Genome & Company had annual revenue of 27.74B with 94.07% growth.
Revenue (ttm)
29.84B
Revenue Growth
+86.35%
P/S Ratio
2.72
Revenue / Employee
304.46M
Employees
98
Market Cap
81.29B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 27.74B | 13.45B | 94.07% |
Dec 31, 2023 | 14.30B | 211.39M | 1.50% |
Dec 31, 2022 | 14.08B | 13.63B | 3,021.27% |
Dec 31, 2021 | 451.25M | 300.66M | 199.67% |
Dec 31, 2020 | 150.58M | 104.75M | 228.54% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Electronics | 308.59T |
SK hynix | 77.21T |
LG Energy Solution | 25.76T |
Samsung Biologics | 4,898.69B |
Hanwha Aerospace | 15.28T |
Hyundai Motor Company | 178.98T |
Doosan Enerbility | 15.88T |
HD Hyundai Heavy Industries | 15.32T |